Sugi Predict

Sugi Predict / Compounds / SCHEMBL1990464

SCHEMBL1990464

SCHEMBL1990464

O=C1CC(NC(=O)C(F)(F)F)c2ccccc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.62
▸ GAA P10253 1/20 0.62
▸ KDM4E B2RXH2 3/20 0.58
▸ ALDH1A1 P00352 2/20 0.58
▸ P2RX7 Q99572 1/20 0.51
▸ TLR9 Q9NR96 1/20 0.45
▸ HTT P42858 2/20 0.42
▸ PARP1 P09874 1/20 0.41
▸ NCOA1 Q15788 1/20 0.40
▸ NCOA3 Q9Y6Q9 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ MTNR1A P48039 1/20 0.37
▸ MTNR1B P49286 1/20 0.37
▸ PGR P06401 1/20 0.36
▸ HSD17B2 P37059 1/20 0.36
▸ GLS O94925 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.35
▸ AR P10275 1/20 0.35
▸ HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29668743 1.00 LMNA (0.62) LMNAGAAKDM4EALDH1A1P2RX7
SCHEMBL1273705 1.00 LMNA (0.62) LMNAGAAKDM4EALDH1A1P2RX7
SCHEMBL20238201 1.00 LMNA (0.62) LMNAGAAKDM4EALDH1A1P2RX7
SCHEMBL29668909 1.00 LMNA (0.62) LMNAGAAKDM4EALDH1A1P2RX7
SCHEMBL15006926 0.85 LMNA (0.47) LMNAGAAKDM4EALDH1A1P2RX7
SCHEMBL1265290 0.85 LMNA (0.47) LMNAGAAKDM4EALDH1A1P2RX7
SCHEMBL1265292 0.85 LMNA (0.47) LMNAGAAKDM4EALDH1A1P2RX7
SCHEMBL8060723 0.85 LMNA (0.46) LMNAGAAKDM4EALDH1A1P2RX7
SCHEMBL31278291 0.81 LMNA (0.69) LMNAGAAKDM4EALDH1A1P2RX7
SCHEMBL2980839 0.80 LMNA (0.71) LMNAGAAKDM4EALDH1A1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497359-B2 Acrylamide derivatives NRG THERAPEUTICS LTD (GB) 2025-12-16 — — US disclosed
EP-4208448-B1 ACRYLAMIDE DERIVATIVES NRG THERAPEUTICS LTD (GB) 2025-04-23 — — EP disclosed
US-20230312466-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-10-05 — — US disclosed
US-20230312466-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-10-05 — — US disclosed
US-20230312466-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-10-05 — — US disclosed
EP-4208448-A1 NOVEL COMPOUNDS NRG Therapeutics LTD (GB) 2023-07-12 — — EP disclosed
CN-116096712-A Novel compounds NRG治疗有限公司 2023-05-09 — — CN disclosed
CN-110325531-B Benzenesulfonamides and their use as therapeutic agents 泽农医药公司 2022-05-27 — — CN disclosed
WO-2022049377-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2022-03-10 — — WO disclosed
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 — — US disclosed
US-20110152381-A1 3-KETO-N-PROPARGYL-1-AMINOINDAN TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2011-06-23 — — US disclosed
US-20110152381-A1 3-KETO-N-PROPARGYL-1-AMINOINDAN TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2011-06-23 — — US disclosed
US-20110152381-A1 3-KETO-N-PROPARGYL-1-AMINOINDAN TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2011-06-23 — — US disclosed
US-7772221-B2 Diaminopropane derived macrocycles as inhibitors of β amyloid production BRISTOL-MEYERS SQUIBB COMPANY (US) 2010-08-10 — — US disclosed
US-20080194535-A1 DIAMINOPROPANE DERIVED MACROCYCLES AS INHIBITORS OF BETA AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY 2008-08-14 — — US disclosed
US-7338974-B2 Macrocyclic diaminopropanes as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-03-04 — — US disclosed
US-7338974-B2 Macrocyclic diaminopropanes as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-03-04 — — US disclosed
WO-2007021793-A1 MACROCYCLIC DIAMINOPROPANES AS BETA-SECRETASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-22 — — WO disclosed
US-20070037868-A1 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome BRISTOL-MYERS SQUIBB COMPANY 2007-02-15 — — US disclosed
US-20070037868-A1 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome BRISTOL-MYERS SQUIBB COMPANY 2007-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194535-A1 DIAMINOPROPANE DERIVED MACROCYCLES AS INHIBITORS OF BETA AMYLOID PRODUCTION APP, BACE1, BACE2 LMNA 489/4885GAA 418/4885KDM4E 4280/4885
US-20230312466-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, UGT1A1 LMNA 3307/4885GAA 1249/4885KDM4E 3516/4885
US-20110152381-A1 3-KETO-N-PROPARGYL-1-AMINOINDAN PKD1, NAT1, AAAS LMNA 1507/4885GAA 1955/4885KDM4E 564/4885
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents KCND2, SCN1A, CACNA1D LMNA 1478/4885GAA 2829/4885KDM4E 1408/4885
US-12497359-B2 Acrylamide derivatives ACR, GSTA2, GSTA1 LMNA 1162/4885GAA 3295/4885KDM4E 4672/4885
US-20070037868-A1 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome APP, BACE1, PSEN1 LMNA 293/4885GAA 463/4885KDM4E 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.